Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice

Arthritis and Rheumatism

Volumn 65, Issue 10, 2013, Pages 2691-2702

  Tsantikos, Evelyn ^a   Maxwell, Mhairi J ^a   Putoczki, Tracy ^b   Ernst, Matthias ^b   Rose John, Stefan ^c   Tarlinton, David M ^d   Hibbs, Margaret L ^a  

^a MONASH UNIVERSITY   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c UNIVERSITY OF KIEL   (Germany)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; NITROGEN; SOLUBLE GP130FC PROTEIN; UNCLASSIFIED DRUG; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLOMERULONEPHRITIS; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UREA NITROGEN BLOOD LEVEL;

AGING; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; INFLAMMATION; INTERLEUKIN-6; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84885126530     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38061     Document Type: Article

References (50)

1. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR,. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991; 147: 117-23.
2. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG,. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol 1992; 90: 106-10.
3. Al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S,. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol 1993; 13: 58-67.
4. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND,. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995; 13: 17-22.
5. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-42.
6. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994; 180: 1243-50.
7. Dalrymple SA, Lucian LA, Slattery R, McNeil T, Aud DM, Fuchino S, et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun 1995; 63: 2262-8.
8. Romani L, Mencacci A, Cenci E, Spaccapelo R, Toniatti C, Puccetti P, et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med 1996; 183: 1345-55.
9. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461-8.
10. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 1998; 95: 8222-6.
11. Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A,. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28: 2178-87.
12. Okuda Y, Sakoda S, Bernard CC, Fujimura H, Saeki Y, Kishimoto T, et al. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int Immunol 1998; 10: 703-8.
13. Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y,. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998; 161: 6480-6.
14. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A,. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011; 70: 755-9.
15. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
16. Chugh PK,. Lupus: novel therapies in clinical development. Eur J Intern Med 2012; 23: 212-8.
17. Merrill JT,. Ending the 50-year drought of FDA drug approval for SLE. Bull NYU Hosp Jt Dis 2011; 69: 238-42.
18. Taga T, Kishimoto T,. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997; 15: 797-819.
19. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ,. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992; 4: 96-100.
20. Mullberg J, Oberthur W, Lottspeich F, Mehl E, Dittrich E, Graeve L, et al. The soluble human IL-6 receptor: mutational characterization of the proteolytic cleavage site. J Immunol 1994; 152: 4958-68.
21. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268: 160-7.
22. Tenhumberg S, Waetzig GH, Chalaris A, Rabe B, Seegert D, Scheller J, et al. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem 2008; 283: 27200-7.
23. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-8.
24. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171: 3202-9.
25. Richards PJ, Nowell MA, Horiuchi S, McLoughlin RM, Fielding CA, Grau S, et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 2006; 54: 1662-72.
26. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008; 111: 1021-8.
27. Jones SA, Scheller J, Rose-John S,. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-83.
28. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995; 83: 301-11.
29. Nishizumi H, Taniuchi I, Yamanashi Y, Kitamura D, Ilic D, Mori S, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995; 3: 549-60.
30. Tsantikos E, Oracki SA, Quilici C, Anderson GP, Tarlinton DM, Hibbs ML,. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J Immunol 2010; 184: 1348-60.
31. Koh AE, Njoroge SW, Feliu M, Cook A, Selig MK, Latchman YE, et al. The SLAM family member CD48 (Slamf2) protects lupus-prone mice from autoimmune nephritis. J Autoimmun 2011; 37: 48-57.
32. Tsantikos E, Maxwell MJ, Kountouri N, Harder KW, Tarlinton DM, Hibbs ML,. Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development. J Immunol 2012; 189: 1726-36.
33. Scapini P, Hu Y, Chu CL, Migone TS, Defranco AL, Cassatella MA, et al. Myeloid cells, BAFF, and IFN-γ establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J Exp Med 2010; 207: 1757-73.
34. McLoughlin RM, Jenkins BJ, Grail D, Williams AS, Fielding CA, Parker CR, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005; 102: 9589-94.
35. Jones GW, McLoughlin RM, Hammond VJ, Parker CR, Williams JD, Malhotra R, et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol 2010; 184: 2130-9.
36. Lissilaa R, Buatois V, Magistrelli G, Williams AS, Jones GW, Herren S, et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol 2010; 185: 5512-21.
37. Tsantikos E, Quilici C, Harder KW, Wang B, Zhu HJ, Anderson GP, et al. Perturbation of the CD4 T cell compartment and expansion of regulatory T cells in autoimmune-prone Lyn-deficient mice. J Immunol 2009; 183: 2484-94.
38. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J,. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010; 16: 701-7.
39. Lau M, Tsantikos E, Maxwell MJ, Tarlinton DM, Anderson GP, Hibbs ML,. Loss of STAT6 promotes autoimmune disease and atopy on a susceptible genetic background. J Autoimmun 2012; 39: 388-97.
40. Liu Z, Davidson A,. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012; 18: 871-82.
41. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
42. Roche. FDA approves ACTERMA for the treatment of moderately to severely active rheumatoid arthritis. January 11, 2010. URL: http://www.roche.com/media/ media-releases/med-cor-2010-01-11.htm.
43. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542-52.
44. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006; 55: 1263-9.
45. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010; 184: 1543-51.
46. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012; 32: 281-90.
47. Maxwell MJ, Tsantikos E, Kong AM, Vanhaesebroeck B, Tarlinton DM, Hibbs ML,. Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease. J Autoimmun 2012; 38: 381-91.
48. Schrezenmeier H, Hochsmann B,. Drugs that inhibit complement. Transfus Apher Sci 2012; 46: 87-92.
49. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA,. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996; 93: 8563-8.
50. De Jorge EG, Macor P, Paixao-Cavalcante D, Rose KL, Tedesco F, Cook HT, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011; 22: 137-45.